Latest revenue
$0
as of 2025-09-30
Latest net income
$-30.6M
as of 2025-09-30
Net margin
—
as of 2025-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AVTX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $687.8M
- Enterprise value
- $663.9M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 10.07×
- Dividend yield
- 0.0%
- 52-wk high
- $24.27
- 52-wk low
- $4.20
- Beta
- —
- Shares out
- 52.6M
5-year trend
What this company does
Table of Contents PART I Item 1. Business. Overview We are a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (“mAb”) is in a Phase 2 clinical trial for hidradenitis suppurativa (“HS”). We are also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. Our current focus is on completing the Phase 2 (“LOTUS”) trial evaluating abdakibart (AVTX-009) in HS, preparing for the anticipated topline data readout in the second quarter of 2026, and planning for our…
AI summary unavailable — showing raw filing excerpt
Generated from AVTX's filing dated 2026-03-23
Key risks
Table of Contents Item 1A. Risk Factors. You should consider carefully the following information about the risks described below, together with the other information contained in this Annual Report on Form 10-K and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price and value of our securities would likely decline. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also harm our business. Moreover, some of the…
AI summary unavailable — showing raw filing excerpt
Generated from AVTX's filing dated 2026-03-23
Profitability
Operating margin
-123601.7%
695.6%Net margin
-132642.4%
1565.2%Return on equity
-94.2%
256.9%Return on assets
-67.2%
188.3%Leverage
Debt / equity
0.40×
202.4%Long-term debt / equity
0.00×
100.0%Debt / assets
28.7%
144.3%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-19.6M | -49.3% | — |
Q4 2025 2025-12-31 | — | — | $-13.7M | -112.6% | — |
Q3 2025 2025-09-30 | $0 | -100.0% | $-30.6M | -14683.3% | — |
Q2 2025 2025-06-30 | — | — | $-20.8M | +9.0% | — |
Q1 2025 2025-03-31 | — | — | $-13.1M | +89.2% | — |
Q4 2024 2024-12-31 | $192.0K | — | $108.8M | — | 56655.2% |
Q3 2024 2024-09-30 | $249.0K | +5.5% | $210.0K | +104.0% | 84.3% |
Q2 2024 2024-06-30 | $0 | -100.0% | $-22.8M | -178.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AVTX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$6.4M
Net activity
−$6.4M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AVTX
Institutional value
$74.0M
Total shares held
5.0M
Distinct holders
28
-56 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 1.1M | $17.0M | +664.2K (+139.0%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 719.7K | $10.7M | — | New |
| 3 | JENNISON ASSOCIATES LLC | 470.8K | $7.0M | -4.8K (-1.0%) | Trimmed |
| 4 | BNP PARIBAS FINANCIAL MARKETS | 422.8K | $6.3M | +225.0K (+113.8%) | Added |
| 5 | KENNEDY CAPITAL MANAGEMENT LLC | 388.0K | $5.8M | — | New |
| 6 | BlackRock, Inc. | 327.1K | $4.9M | +37.5K (+13.0%) | Added |
| 7 | NAN FUNG TRINITY (HK) LTD | 189.0K | $2.8M | +0 (+0.0%) | No change |
| 8 | JPMORGAN CHASE & CO | 194.4K | $2.7M | +150.0K (+337.5%) | Added |
| 9 | JANE STREET GROUP, LLC | 173.3K | $2.6M | -5.5K (-3.1%) | Trimmed |
| 10 | abrdn plc | 171.7K | $2.6M | +76.3K (+79.9%) | Added |
| 11 | Hudson Bay Capital Management LP | 161.1K | $2.4M | +144.3K (+860.5%) | Added |
| 12 | Moody Aldrich Partners LLC | 159.3K | $2.4M | +26.1K (+19.6%) | Added |
| 13 | DEUTSCHE BANK AG\ | 150.0K | $2.2M | +0 (+0.0%) | No change |
| 14 | VANGUARD FIDUCIARY TRUST CO | 86.4K | $1.3M | — | New |
| 15 | SEI INVESTMENTS CO | 56.9K | $848.8K | — | New |
| 16 | TD ASSET MANAGEMENT INC | 51.4K | $767.5K | — | New |
| 17 | DIMENSIONAL FUND ADVISORS LP | 40.8K | $607.3K | — | New |
| 18 | ENVESTNET ASSET MANAGEMENT INC | 20.0K | $298.5K | +4.0K (+24.7%) | Added |
| 19 | WESTFIELD CAPITAL MANAGEMENT CO LP | 15.6K | $233.5K | — | New |
| 20 | AlphaCentric Advisors LLC | 11.7K | $174.2K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AVTX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.